相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
Maria Romina Girotti et al.
CANCER CELL (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
Neroshan Thevakumaran et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
Jean-Francois Emile et al.
BLOOD (2014)
Somatic activating ARAF mutations in Langerhans cell histiocytosis
David S. Nelson et al.
BLOOD (2014)
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
Rikhia Chakraborty et al.
BLOOD (2014)
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L. Diamond et al.
BLOOD (2014)
Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation
Baptiste Hervier et al.
BLOOD (2014)
Frequent detection of BRAFV600E mutations in histiocytic and dendritic cell neoplasms
Heounjeong Go et al.
HISTOPATHOLOGY (2014)
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia
Niuscha Yaktapour et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Kinases and Pseudokinases: Lessons from RAF
Andrey S. Shaw et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
Julien Haroche et al.
BLOOD (2013)
Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia
Sascha Dietrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R-Mutated Melanoma
Philippe Bahadoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Alyson K. Freeman et al.
MOLECULAR CELL (2013)
Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma
Hidefumi Sasaki et al.
LUNG CANCER (2013)
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization
Hugo Lavoie et al.
NATURE CHEMICAL BIOLOGY (2013)
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
Guangwu Guo et al.
NATURE GENETICS (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
BRAF V600E Inhibition in Anaplastic Thyroid Cancer
Michael H. Rosove et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting the BRAF V600E Mutation in Multiple Myeloma
Mindaugas Andrulis et al.
CANCER DISCOVERY (2013)
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Julien Haroche et al.
BLOOD (2012)
Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways
Neerav Shukla et al.
CLINICAL CANCER RESEARCH (2012)
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
Michael Roering et al.
EMBO JOURNAL (2012)
The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
Catherine Andreadi et al.
GENES & DEVELOPMENT (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Dissecting the genomic complexity underlying medulloblastoma
David T. W. Jones et al.
NATURE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
David Capper et al.
ACTA NEUROPATHOLOGICA (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1
S. Huber et al.
LEUKEMIA (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers
Shin Yup Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
Jared A. Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome
P Rodriguez-Viciana et al.
SCIENCE (2006)
Germline mutations in HRAS proto-oncogene cause Costello syndrome
Y Aoki et al.
NATURE GENETICS (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
A Tannapfel et al.
GUT (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
